MECHANISM OF ACTION
SLU-PP-332 is not a peptide, it's a small molecule that works like a key for a group of switches inside the cell nucleus called ERRs (estrogen-related receptors, named for their structure, not because they affect estrogen). These switches control genes that respond to aerobic exercise: building more mitochondria (power plants in muscle cells), burning fat for fuel, and improving oxygen use. When SLU-PP-332 activates all three ERR switches at once, it triggers the same gene activity as a long cardio session, without the physical exercise. In research animals, it increased running endurance by around 70% over four weeks. It's one of the newest compounds in the exercise-mimetic category and has no established human dose yet.
RESEARCH APPLICATIONS
- Exercise mimetic research - endurance and VO2 max modelling
- Mitochondrial biogenesis upregulation
- Fatty acid oxidation and metabolic efficiency
- Heart failure and muscle wasting models
- Combination with AMPK activators (MOTS-C)
RESEARCH HIGHLIGHTS
Endurance Enhancement
2023SLU-PP-332 (4 weeks, research-dose IP) increased running capacity by ~70% vs. controls and upregulated PGC-1α, VEGF, and oxidative metabolism genes in skeletal muscle.
Ref: Banerjee et al., J Med Chem
ERR Trifecta Agonism
2023Structural studies confirm simultaneous agonism at ERRα, β, and γ - activating a broader transcriptional programme than selective ERR agonists.
Ref: Pourcet et al., Nat Chem Biol
RESEARCH PROTOCOL NOTES
Chemical Identity
Storage & Stability
Small molecule - stable at 2–8°C. Protect from light. Less degradation-sensitive than peptides.
Regulatory Status
Very early-stage research compound. No clinical trials. Not WADA prohibited (not yet on radar). SA: unscheduled research compound.